-+ 0.00%
-+ 0.00%
-+ 0.00%

Incyte posts 24-week TRuE-AD4 data on long-term safety of ruxolitinib cream in moderate atopic dermatitis at EADV 2026

PUBT·09/22/2026 12:34:09
Incyte posts 24-week TRuE-AD4 data on long-term safety of ruxolitinib cream in moderate atopic dermatitis at EADV 2026
  • Incyte flagged new clinical and real-world data across its inflammation and autoimmunity portfolio for presentation at EADV 2026 in Vienna.
  • Key readouts center on ruxolitinib cream in moderate atopic dermatitis, including longer-term safety, patient-reported benefits, and reduced need to escalate therapy.
  • Povorcitinib Phase 3 analyses in hidradenitis suppurativa highlight improvements across clinical outcomes, patient-reported burden, and biomarkers in higher-burden patients.
  • Additional studies outline market and utilization dynamics in prurigo nodularis, including prevalence, treatment patterns, and healthcare resource use in the US and Germany.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Incyte Corporation published the original content used to generate this news brief via Business Wire (Ref. ID: 202609220830BIZWIRE_USPR_____20260922_BW373347) on September 22, 2026, and is solely responsible for the information contained therein.